This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
biotechnology: Archive
Should You Buy TEGNA Inc. (TGNA) After Golden Cross?
by Zacks Equity Research
Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?
TGNAPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
InfuSystems Holdings, Inc. (INFU)'s Technical Outlook is Bright After Key Golden Cross
by Zacks Equity Research
Should investors be excited or worried when a stock's 50-day simple moving average crosses above the 200-day simple moving average?
INFUPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
After Golden Cross, United Bankshares (UBSI)'s Technical Outlook is Bright
by Zacks Equity Research
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
UBSIPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Coya Therapeutics, Inc. (COYA) Now Trades Above Golden Cross: Time to Buy?
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
COYAPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Should You Buy Paymentus (PAY) After Golden Cross?
by Zacks Equity Research
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
PAYNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
SNDL Inc. (SNDL)'s Technical Outlook is Bright After Key Golden Cross
by Zacks Equity Research
Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?
SNDLPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Webtoon Entertainment (WBTN)'s Technical Outlook is Bright After Key Golden Cross
by Zacks Equity Research
Should investors be excited or worried when a stock's 50-day simple moving average crosses above the 200-day simple moving average?
WBTNPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Brilliant Earth Group, Inc. (BRLT)'s Technical Outlook is Bright After Key Golden Cross
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
BRLTPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Nuvation Bio Inc. (NUVB) Just Flashed Golden Cross Signal: Do You Buy?
by Zacks Equity Research
Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?
NUVBNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Should You Buy Sotera Health Company (SHC) After Golden Cross?
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
SHCNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
New Strong Sell Stocks for August 27th
by Zacks Equity Research
CVGI, INBK and MNKD have been added to the Zacks Rank #5 (Strong Sell) List on August 27, 2025.
MNKDPositive Net Change CVGIPositive Net Change INBKPositive Net Change
biotechnology
Catalyst Pharmaceuticals Settles Firdapse Patent Litigation With Lupin
by Zacks Equity Research
CPRX secures a key win as its Firdapse patent litigation settlement with Lupin shields U.S. sales from generic competition until 2035.
CPRXPositive Net Change CRMDPositive Net Change KNSAPositive Net Change PHARNegative Net Change
biotechnology biotechs medical pharmaceuticals
Can Novo Nordisk Offset GLP-1 Pressures With Rare Disease Wins?
by Ahan Chakraborty
NVO faces slowing GLP-1 momentum but leans on rare disease wins and new Wegovy approval to bolster growth.
NVOPositive Net Change LLYPositive Net Change VKTXPositive Net Change
biotechnology biotechs medical pharmaceuticals
Enerflex (EFXT)'s Technical Outlook is Bright After Key Golden Cross
by Zacks Equity Research
Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?
EFXTPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
ScanSource (SCSC)'s Technical Outlook is Bright After Key Golden Cross
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
SCSCPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Central Pacific Financial (CPF) Now Trades Above Golden Cross: Time to Buy?
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
CPFPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
GILD Wins Approval for Twice-Yearly HIV Prevention Shot in the EU
by Zacks Equity Research
Gilead secures EU approval for twice-yearly HIV prevention shot Yeytuo, backed by strong trial data and expanded market protection.
GSKNegative Net Change PFEPositive Net Change GILDPositive Net Change CVSPositive Net Change
biotechnology biotechs medical pharmaceuticals
Can Label Expansion of Cabometyx Fuel Further Growth for EXEL?
by Ekta Bagri
The FDA approval to expand Exelixis' Cabometyx into neuroendocrine tumors is witnessing encouraging uptake and boosting investor focus.
NVSNegative Net Change MRKPositive Net Change EXELPositive Net Change
biotechnology biotechs medical pharmaceuticals
PGEN Stock Surges 144% in August on FDA Nod for Rare Lung Disease Drug
by Zacks Equity Research
Precigen stock soars 144% in August after FDA approval of Papzimeos, the first treatment for adults with recurrent respiratory papillomatosis.
INOPositive Net Change CRMDPositive Net Change KNSAPositive Net Change PGENNegative Net Change
biotechnology biotechs gene-editing gene-therapy medical pharmaceuticals
Should You Buy Aveanna Healthcare (AVAH) After Golden Cross?
by Zacks Equity Research
Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?
AVAHPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Backblaze, Inc. (BLZE) Just Flashed Golden Cross Signal: Do You Buy?
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
BLZEPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
SiteOne Landscape (SITE)'s Technical Outlook is Bright After Key Golden Cross
by Zacks Equity Research
Should investors be excited or worried when a stock's 50-day simple moving average crosses above the 200-day simple moving average?
SITEPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Exelixis vs. Merck: Which Oncology Stock Is a Better Pick as of Now?
by Ekta Bagri
EXEL rides on Cabometyx momentum and pipeline gains, while MRK leans on Keytruda dominance and a diverse portfolio for growth.
MRKPositive Net Change EXELPositive Net Change
biotechnology biotechs medical pharmaceuticals
BMY vs GSK: Which Biopharma Bigwig Has Better Prospects for Now?
by Ekta Bagri
Bristol Myers leans on new launches to offset legacy drug declines, while GSK's diverse portfolio and strong HIV lineup keep growth on track.
GSKNegative Net Change BMYNegative Net Change
biotechnology biotechs medical pharmaceuticals
After Golden Cross, Alector (ALEC)'s Technical Outlook is Bright
by Zacks Equity Research
Should investors be excited or worried when a stock's 50-day simple moving average crosses above the 200-day simple moving average?
ALECPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines